Baxter International, Inc.

911 articles with Baxter International, Inc.

• Baxter and AdventHealth Tampa Announce Cost Savings Achieved Through Intraoperative Hemostasis Management Program

  12/3/2020

  Companies partner through Baxter’s Vital Edge program, which offers actionable insights and practical solutions to enhance intraoperative hemostasis and blood management strategies

• Baxter BioPharma Solutions Announces $50 Million Investment to Expand Sterile Fill/Finish Manufacturing Site in Bloomington, Ind.

  11/24/2020

  Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced a $50 million expansion of its sterile fill/finish manufacturing facilities located in Bloomington, Ind

• Baxter Announces U.S. FDA 510(k) Clearance of Homechoice Claria with Sharesource

  11/23/2020

  Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource connectivity platform.

• Baxter to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

  11/18/2020

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 3rd Annual HealthCONx virtual conference via webcast on Tuesday, December 1, 2020.

• Baxter Declares Quarterly Dividend - Nov 16, 2020

  11/16/2020

  Baxter International Inc., a leading global medical products company, announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock.

• Baxter Reports Third-Quarter 2020 Results

  10/29/2020

  Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12% Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis

• Baxter Announces Proposed $650 Million Senior Notes Offering

  10/29/2020

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that it proposes to offer, subject to market conditions and other factors, $650 million aggregate principal amount of senior notes due 2031 (the “Notes”). The Notes will be offered and sold only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”),

• Baxter Supports New Study Showing Blood Purification With Oxiris Filter Set Can Play a Role in the Management of Severely Ill COVID-19 Patients

  10/27/2020

  Marks largest study of its kind on COVID-19 patients treated with extracorporeal blood purification (EBP) using Oxiris Study investigators assessed serum IL-6 levels, indicators of organ dysfunction and intensive care unit (ICU) mortality rate in patients undergoing EBP with Oxiris Findings provide clinicians with new insights on EBP initiation in COVID-19 patients

• Baxter to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

  10/15/2020

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via webcast on Monday, November 9, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:45 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Nov

• Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care

  10/14/2020

  Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care Study is first to demonstrate importance of using indirect calorimetry (IC) to measure variable and dynamic energy needs of COVID-19 patients in the intensive care unit Data gathered from Q-NRG+ metabolic monitor device shows variance in resting energy expenditure (REE) measurements in comparison to frequently uti

•  Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition

  9/23/2020

    Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition   New formulations provide up to 60% more protein (amino acid) than current Clinimix formulations while delivering less dextrose 1

• Baxter Announces Exclusive Distribution Agreement With bioMérieux for Novel Acute Kidney Injury Diagnostic Test in Europe and U.S.

  9/16/2020

  Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced a distribution agreement with bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, for the NEPHROCLEARTM CCL14 diagnostic test.

• CORRECTING and REPLACING Baxter to Host Third-Quarter 2020 Financial Results Conference Call for Investors

  9/9/2020

  Baxter International Inc., a leading global medical products company, will host a conference call to discuss its third-quarter 2020 financial results on Thursday, October 29, 2020, at 7:30 a.m. Central Time.

• Baxter to Host Third-Quarter 2020 Financial Results Conference Call for Investors

  9/9/2020

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2020 financial results on Thursday, October 29, 2020, at 7:30 a.m. Central Time.

• Baxter Announces U.S. FDA De Novo Authorization for Theranova Dialyzers Enabling HDx Therapy

  8/31/2020

  U.S. patients with kidney failure now have access to expanded hemodialysis (HDx) therapy delivered by Theranova, a new class of dialyzer Theranova dialyzer’s unique membrane design offers a filtration profile that more closely mimics that of the natural kidney and can be used with existing hemodialysis machines 1,2 Theranova was reviewed by FDA through the De Novo process, a pathway for novel low- to moderate-risk devices

• Baxter to Present at the Virtual Morgan Stanley 18th Annual Global Healthcare Conference

  8/20/2020

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the virtual Morgan Stanley 18 th Annual Global Healthcare Conference via webcast on Wednesday, September 16, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 12:30 p.m. Eastern Time. The live webcast

• Baxter to Present at the 2020 Wells Fargo Virtual Healthcare Conference

  8/19/2020

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 2020 Wells Fargo Virtual Healthcare Conference via webcast on Wednesday, September 9, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:00 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through October

• Baxter Obtains U.S. FDA Emergency Use Authorization for Regiocit Replacement Solution Used in CRRT

  8/14/2020

  Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Regiocit, the company’s replacement solution that contains citrate for regional citrate anticoagulation of the extracorporeal circuit.

• Baxter Obtains U.S. FDA Emergency Use Authorizations for HF20 Set and ST Set Used in CRRT During Covid-19 Pandemic

  8/12/2020

  Provides additional options to help meet increased demand for continuous renal replacement therapy (CRRT) products resulting from COVID-19 pandemic Most recent example of Baxter’s efforts to increase supply of dialysis products used in an acute care environment DEERFIELD, Ill.--( BUSINESS WIRE )-- Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorizations (EUAs) from the U.S.

• Baxter Introduces Virtual Peritoneal Dialysis Excellence Academy for Nurses in the U.S.

  8/5/2020

  First-of-its-kind curriculum educates peritoneal dialysis (PD) nurses in one easily accessible resource Learners earn continuing education (CE) credits and expand knowledge on PD management best practices Trainings offered in interactive, on-demand, and self-guided formats